ID   WM39
AC   CVCL_2240
SY   WM-39; WM 39; WC00077
DR   CLO; CLO_0009618
DR   ATCC; CRL-2811
DR   BioSample; SAMN03471795
DR   Coriell; WC00077
DR   Cosmic; 686399
DR   Cosmic; 1155549
DR   Cosmic; 1187580
DR   Cosmic; 2159437
DR   Cosmic; 2163807
DR   ESTDAB; ESTDAB-080
DR   GEO; GSM109041
DR   GEO; GSM186486
DR   GEO; GSM186487
DR   GEO; GSM186488
DR   GEO; GSM555136
DR   GEO; GSM555171
DR   Progenetix; CVCL_2240
DR   Wikidata; Q54994301
RX   PubMed=2253310;
RX   PubMed=4053039;
RX   PubMed=15592718;
RX   PubMed=16827748;
RX   PubMed=18632627;
RX   PubMed=18790768;
RX   PubMed=21343389;
RX   PubMed=23851445;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
WW   https://www.rockland-inc.com/Product.aspx?id=51871
CC   Part of: Wistar Institute melanoma cell line collection.
CC   HLA typing: A*02:01,02:05; B*07:02,15:03; C*07:02,15:05; DPB1*04:02,02:01:02; DQB1*05:01,02:01; DRB1*01:01,07:01 (PubMed=15592718).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=16827748; PubMed=18632627; PubMed=23851445; Wistar).
CC   Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Unspecified (PubMed=23851445; Wistar).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45ins4aa (c.134ins12bp); Zygosity=Unspecified (PubMed=23851445).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: Amelogenin: X->X,Y.
CC   Discontinued: ATCC; CRL-2811; true.
CC   Discontinued: Coriell; WC00077; probable.
ST   Source(s): ATCC; ESTDAB; Wistar
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 10,12
ST   D16S539: 12
ST   D18S51: 12,16
ST   D19S433: 15,16
ST   D21S11: 30
ST   D2S1338: 17,19
ST   D3S1358: 18
ST   D5S818: 11
ST   D7S820: 14
ST   D8S1179: 13,15
ST   FGA: 20,22
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 23
//
RX   PubMed=2253310; DOI=10.1007/BF00046337;
RA   Herlyn M.;
RT   "Human melanoma: development and progression.";
RL   Cancer Metastasis Rev. 9:101-112(1990).
//
RX   PubMed=4053039;
RA   Herlyn M., Thurin J., Balaban G., Bennicelli J.L., Herlyn D.,
RA   Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H.,
RA   Koprowski H.;
RT   "Characteristics of cultured human melanocytes isolated from different
RT   stages of tumor progression.";
RL   Cancer Res. 45:5670-5676(1985).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431;
RA   Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B., Egyhazi S.,
RA   Hansson J., Wu H., King A.J., Van Belle P., Elder D.E., Flaherty K.T.,
RA   Herlyn M., Nathanson K.L.;
RT   "Increased cyclin D1 expression can mediate BRAF inhibitor resistance
RT   in BRAF V600E-mutated melanomas.";
RL   Mol. Cancer Ther. 7:2876-2883(2008).
//
RX   PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958;
RA   Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M.,
RA   Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R.,
RA   Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E.,
RA   Ostrer H., Osman I.;
RT   "Integrative genomics identifies molecular alterations that challenge
RT   the linear model of melanoma progression.";
RL   Cancer Res. 71:2561-2571(2011).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//